Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANCHOR: Treatment of Anal HSIL in HIV+ Patients
NCT02135419Phase 3Completed
- Sponsor
- AIDS Malignancy Consortium
- Start
- Sep 2014
- Primary completion
- Aug 2021
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by AIDS Malignancy Consortium. Primary endpoint: Anal Cancer Incidence up to 5 years. Started Sep 2014; status: completed.
Beyond the preview
Go deeper on NCT02135419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02135419.